Navigation Links
Decade-long trial confirms benefts of steroid withdrawal for transplant patients
Date:8/23/2010

CINCINNATIA University of Cincinnati (UC) analysis of 10 years of data from local kidney transplant patients shows that patients removed from a corticosteroid regimen shortly after surgery have better graft survival rates, better survival rates and fewer cardiovascular events than patients kept on the traditional regimen of long-term steroids.

The analysis shows that, out of 904 patients transplanted at UC Health University Hospital and Christ Hospital, early corticosteroids withdrawal (ECSWD) patients had an 83.8 percent graft survival rate and a 91.7 percent patient survival rate, as compared to 68.6 percent graft survival and 83.6 percent patient survival for chronic corticosteroid (CCS) patients. UC's survival rates were numerically higher than national rates from the United Network for Organ Sharing (UNOS) registry.

Corticosteroids, in combination with other immunosuppressive drugs, have historically been prescribed to transplant patients to help suppress the body's immune response and allow the transplanted organ to function after surgery. But they also come with an increased risk of high blood pressure, high cholesterol, weight gain, diabetes and cardiovascular disease and events.

With development of better immunosuppressive drugs, that cardiovascular risk has come to be the chief concern for transplant patients' survival, not the loss of their new organ, explains Adele Rike Shields, PharmD, UC research assistant professor of surgery and clinical transplant pharmacist at Christ Hospital.

Four years ago, Shields says, UC researchers showed ECSWD patients had a significant reduction in cardiovascular events as opposed to CCS patients. But researchers still weren't certain whether ECSWD patients have worse long-term graft functioning due to a risk of acute rejection of the organ.

With 10 years of data, Shields says they can now answer that question definitively.

"This is the first study with enough long-term follow-up to show that we're not causing an increase in graft loss with early corticosteroid withdrawal," says Shields. "We have just as good, if not better graft results and the patients' survival is better because of their reduced cardiovascular risk."

She presented the work last week at the International Congress of The Transplantation Society in Vancouver.

Not only does the analysis show that ECSWD patients have decreased cardiovascular events, Shields says they also have a reduced risk of malignancies not associated with immunosuppressive drugs. ECSWD patients showed a 2.2 percent rate of non-PTLD cancer, one-third the rate of malignancies in CCS patients. PTLD, or post-transplant lymphoproliferative disorder, is the name given to a group of lymphomas occurring in immunosuppressed patients.

UC transplant researchers have focused on steroid withdrawal under E. Steve Woodle, MD, chief of the division of transplant surgery. Woodle calls the data from the 10-year analysis "highly statistically significant."

"To my knowledge, we are the first of any transplant program to demonstrate this magnitude of an effect," he says. "We now know without a doubt that our original hypothesis generated more than 15 years ago does indeed benefit our patients. This is the final nail in the coffin for steroid based immunosuppression for our program."


'/>"/>

Contact: Katy Cosse
kathryn.cosse@uc.edu
513-558-0207
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Trial Therapy Improves Melanoma Survival
2. CRF announces featured clinical trials to be presented at TCT 2010
3. Clinical trials: Comprehension unaffected by simplified consent forms or payment
4. Clinical trials abroad: Making non-English language consent forms readable
5. Human clinical trial of NIH-developed dengue vaccine begins
6. CRF announces late breaking trials and first report investigations to be presented at TCT 2010
7. Drug trials funded by industry are more likely to publish favorable results
8. Clinical trials can be improved by managing the learning curve
9. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
10. Microbicide trial results a turning point for HIV prevention, says team testing same gel
11. Many False-Positive HIV Test Results for Those in AIDS Vaccine Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
Breaking Medicine Technology: